Endocyte Anticipating Positive CHMP Opinion On Ovarian Cancer Drug/Diagnostic Combo
This article was originally published in The Pink Sheet Daily
Executive Summary
Endocyte and Merck are preparing to launch a combo drug/diagnostic in folate receptor-positive platinum-resistant ovarian cancer, a condition with a very poor survival prognosis, later this year in the EU. Medical affairs staff are meeting with specialists to discuss how the diagnostic can target patients most likely to respond in pre-approval commercial efforts.